CD27 is a co-stimulatory molecule that provides a complementary target for the PD-1/PD-L1 checkpoint axis on T cells. Here, researchers developed CDX-527, a tetravalent PD-L1xCD27 IgG1-scFv bispecific antibody (BsAb). CDX-527 potently inhibits PD-1 signaling and induces CD27-mediated T cell co-stimulation via PD-L1 cross-linking. In a mixed lymphocyte reaction assay, CDX-527 outperformed the combination of parental antibodies, suggesting that cross-linking via Fc receptors and PD-L1 enhances CD27 agonist activity. CDX-527 has been shown to mediate effector functions against tumor cells overexpressing CD27 or PD-L1. In human CD27 transgenic mice, researchers observed that antigen-specific T cell responses to vaccines were significantly enhanced using an alternative PD-L1xCD27 BsAb. In addition, in a syngeneic lymphoma model, this BsAb showed higher antitumor activity than the parental antibody combination. Preliminary studies of CDX-527 in cynomolgus monkeys confirmed its mAb-like pharmacokinetic characteristics without significant toxicity. These studies showed that CDX-527 effectively combines PD-1 blockade and CD27 co-stimulation into a single molecule with greater potency than the parental antibody combination, which provides a theoretical basis for advancing clinical research of this BsAb in cancer patients.
BsAbs are designed to enhance T cell immunity, and CDX-527 binds to activated FcγRs, potentially mediating effector functions such as ADCC against certain tumor cells that overexpress PD-L1 or CD27. CDX-527 induced ADCC in tumor cell lines endogenously expressing PD-L1 or CD27 or in cells transfected with these receptors, although the BsAb was slightly less potent than the parental 2B3 mAb in CD27-expressing cells (Figure 1a-d). To confirm target specificity, 9H9 induced ADCC only in PD-L1-expressing cells but not in CD27-expressing cells, while 2B3 induced ADCC in CD27-expressing cells but not in PD-L1-expressing cells. CDX-527 did not exhibit measurable complement-mediated cytotoxicity against the same cell lines.
Figure 1. CDX-527 mediated ADCC. (Vitale L A, et al., 2020)
Customer Q&As
What is the potential application of the Human CD27 Stable Cell Line - HEK293T in tumor immunotherapy research?
A: The Human CD27 Stable Cell Line - HEK293T, with stable expression of the CD27 receptor, holds significant potential for tumor immunotherapy research. CD27 is a crucial immunoregulatory receptor, and its activation can enhance the immune responses of T cells and B cells. This cell line can be used to study the role of CD27 in tumor immune evasion and anti-tumor immune responses.
How can the regulatory mechanisms of the CD27 signaling pathway be studied using the Human CD27 Stable Cell Line - HEK293T?
A: By using the Human CD27 Stable Cell Line - HEK293T, various biochemical and molecular biology experiments can be conducted to study the regulatory mechanisms of the CD27 signaling pathway. For example, immunoprecipitation and mass spectrometry can be used to identify proteins interacting with CD27, and reporter gene analysis can monitor the activity of the CD27 signaling pathway.
How should experiments be designed for antibody screening using the Human CD27 Stable Cell Line - HEK293T?
A: For antibody screening, experiments should be designed to assess the binding capacity and functional impact of different candidate antibodies on the CD27 receptor in the Human CD27 Stable Cell Line - HEK293T. Techniques like flow cytometry or ELISA can be used to evaluate the binding affinity and antigen specificity of antibodies.
What is the application of the Human CD27 Stable Cell Line - HEK293T in simulating a chronic inflammation environment?
A: The Human CD27 Stable Cell Line - HEK293T can be used to simulate a chronic inflammation environment to study the role and regulatory mechanisms of CD27 in chronic inflammation. By simulating chronic inflammatory conditions, the effects of CD27 on immune cell activation, cytokine production, and cell migration can be studied.
What key factors should be considered when conducting gene editing experiments with the Human CD27 Stable Cell Line - HEK293T?
A: When conducting gene editing experiments, it is important to select appropriate targets and use efficient and specific gene editing technologies, such as the CRISPR/Cas9 system. Detailed molecular and cellular level validations are needed to ensure the accuracy of gene editing and its impact on CD27 expression and function.
What is the potential application of the Human CD27 Stable Cell Line - HEK293T in studying autoimmune diseases?
A: The Human CD27 Stable Cell Line - HEK293T has potential applications in the study of autoimmune diseases. CD27 plays a crucial role in regulating the activation and differentiation of T cells and B cells, and this cell line can be used to investigate the mechanisms of CD27 in autoimmune diseases and potential therapeutic targets.
Ask a Question